RNA vaccines to prevent cancer in people with Lynch syndrome and early lung lesions
CAP-IT Center for LNP RNA Immunoprevention
This center is creating RNA-based vaccines meant to help people with Lynch syndrome and those who have early lung precursor nodules avoid developing cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11166674 on NIH RePORTER |
What this research studies
From a patient's perspective, this center is designing nucleic-acid (RNA) vaccines that target shared tumor markers found in people with Lynch syndrome and abnormal cells in early lung nodules. Researchers will use genomic analyses, spatial tissue mapping, and immunopeptidomics to find the best targets and then formulate those targets into lipid-nanoparticle RNA vaccines. The vaccines will be optimized and tested in the lab and preclinical models to select the safest, most promising candidates. The goal is to prepare vaccine candidates for early human prevention trials and eventual clinical use.
Who could benefit from this research
Good fit: Ideal candidates would be people with a confirmed diagnosis of Lynch syndrome or individuals identified with non-solid lung nodules thought to be pre-malignant.
Not a fit: People without a genetic cancer predisposition or without lung precursor lesions are unlikely to gain direct benefit from these specific vaccines.
Why it matters
Potential benefit: If successful, these vaccines could reduce or prevent cancer development in high-risk people with Lynch syndrome or pre-malignant lung nodules.
How similar studies have performed: mRNA and nucleic-acid vaccine approaches have shown promise in infectious disease and some cancer immunotherapy settings, but preventive RNA vaccines for hereditary cancers and lung precursor lesions are largely novel and untested in humans.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Mittal, Vivek — Weill Medical Coll of Cornell Univ
- Study coordinator: Mittal, Vivek
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.